Navigation Links
CIMZIA(R) (Certolizumab Pegol) Provides Long-Term Benefit Without Dose Escalation in Crohn's Disease Patients
Date:10/7/2008

.

WELCOME Study (Abstract #P283)

Data from the Phase IIIb WELCOME study showed that 39 percent of patients who responded to CIMZIA treatment after failing infliximab therapy achieved clinical remission at Week 6 as measured by the Crohn's Disease Activity Index (CDAI). In addition, the study found that 61 percent of study patients reduced CDAI symptom scores by 100 points and 68 percent reduced CDAI scores by 70 points. The CDAI is a patient/physician questionnaire which incorporates eight CD-related variables. Scores of <150 indicate remission, and scores of >450 indicate severe illness along the 600 point scale.

Response to CIMZIA was similar when used as a monotherapy or with concomitant corticosteroids or immunosuppressants. There were also no differences in clinical responses to CIMZIA among those patients who had previously lost response to infliximab (62 percent), were hypersensitive to infliximab (61 percent) or both (58 percent).

PRECiSE 3 Study (Abstract #P280)

The PRECiSE 3 (P3) open-label extension study of PRECiSE 1 and PRECiSE 2 was designed to evaluate the longer-term safety and effectiveness of CIMZIA in patients completing the other two studies. The 30-month analysis includes data from 141 patients who have been continuously treated with CIMZIA for 2.5 years. At the beginning of P3, 73 percent of CIMZIA-treated patients were in remission. After 2.5 years (30 months) of treatment with CIMZIA, 72 percent of patients were in remission based upon responder analysis. The incidence of injection site pain was low in the CIMZIA group, and no new safety signals observed over 2.5 years of active treatment.

Pharmacoeconomics Study (Abstract #P277)

A cost analysis for induction and maintenance dosing regimens for CIMZIA, infliximab and adalimumab was estimated for a 65kg patient over a two-year period. Response and remission rates were assumed the same between treatments, and maintenance therapy was followed if r
'/>"/>

SOURCE UCB
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related medicine technology :

1. CIMZIA(R) (certolizumab pegol), Significantly Reduces Structural Damage and Rheumatoid Arthritis Signs & Symptoms for Up to One Year
2. Cimzia(R) Provides Long-Term Efficacy with Stable Dosing in Crohns Disease
3. CIMZIA(R) (certolizumab pegol) Reduces Intestinal Lesions and Induces Endoscopic Improvement in Crohns Patients
4. CuraGen Provides Update on Velafermin, Belinostat and CR011-vcMMAE Clinical Development Programs
5. Access Pharmaceuticals Provides Update on Clinical Development Plan of ProLindac
6. Study Shows Combination Therapy Incorporating AVODART(R) and Tamsulosin Provides Continuous Symptom Improvement Over 2 Years
7. Raptor Pharmaceuticals Provides Update of Product Programs
8. Monogram Provides Update on Trofile(TM) Co-Receptor Tropism Assay
9. Arbios Provides Clinical Strategy for SEPET(TM) Pivotal Trial
10. Innocoll Provides a Progress Update on its Clinical Development Programs and Specialty Pharmaceutical Operations
11. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/24/2014)... FARMINGTON, Conn. , Dec. 24, 2014 ... a biopharmaceutical company developing targeted, receptor-specific peptide therapeutics ... medical need and commercial potential, today announced that ... 2,050,000 shares of its common stock and Series ... common stock.  Funds under the management of QVT ...
(Date:12/24/2014)... ResMed (NYSE: RMD ) today announced its victory ... manufacturer BMC Medical Co., Ltd. The International ... infringe ResMed,s patents, and entered an order prohibiting BMC from ... United States : , iVolve nasal mask ... pillows mask , iVolve full face mask ...
(Date:12/24/2014)... ALEXANDRIA, Va. , Dec. 23, 2014 /PRNewswire-USNewswire/ ... stringent diastolic blood pressure target for people with ... either moderate or high doses of statins, in ... risk management enacted by the American College of ... recommendations are reflected in the most recent changes ...
Breaking Medicine Technology:Palatin Completes $20 Million Equity and $10 Million Debt Financings 2Palatin Completes $20 Million Equity and $10 Million Debt Financings 3Palatin Completes $20 Million Equity and $10 Million Debt Financings 4ResMed Wins Patent Infringement Lawsuit Against Chinese Manufacturer BMC Medical 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 2New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 3New Standards of Care Provide Guidelines for Statin Use for People with Diabetes to Prevent Heart Disease 4
... SAN DIEGO, Oct. 7 CareFusion Corporation (NYSE: CFN ) ... 2010 on Tuesday, Nov. 10 following the close of trading on ... webcast and conference call on Nov. 10 at 2:00 pm Pacific ... first quarter, ended on Sep. 30, 2009. To access the call ...
... October 7 DBMS Consulting announced that it,has successfully ... Oracle E-Business Suite (EBS) for SIRO Clinpharm, one of ... fully,automated capabilities in management of clinical trial process, clinical,trial ... After this implementation, SIRO gains complete operational ...
Cached Medicine Technology:CareFusion Will Host An Earnings Conference Call on November 10, 2009 to Discuss the Results for the First Quarter of Fiscal 2010 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 2DBMS Consulting Successfully Completes Roll out of Oracle Health Sciences Applications (OHSA) Suite for SIRO Clinpharm 3
(Date:12/25/2014)... (PRWEB) December 26, 2014 ... BambooFlooringChina.com combines beauty, strength and durability. Today, the ... promotion, which is valid until Jan. 30, 2015. ... grain of traditional hardwood. BambooFlooringChina.com is a well-known ... help consumers worldwide to find a reliable bamboo ...
(Date:12/25/2014)... “Every three months the trends for evening dresses ... will be one of the hottest styles in the next ... the company releases 26 A-line sweetheart evening dresses, and announces ... , “We are trying our best to help a lady ... Along with affordable prices, we provide discounted delivery costs to ...
(Date:12/25/2014)... Recently, BellasDress has launched its Christmas ... BellasDress has chosen their best-selling lace wedding dresses, vintage ... holiday season. , Now, BellasDress.com features popular women’s ... at discount prices. The business hopes everyone can have ... , “All our elegant products are made with ...
(Date:12/25/2014)... Recently, LunaDress.co.uk has updated its blog to provide professional shopping ... of the models at LunaDress.co.uk come with big discounts, up to ... veil can turn out to be a most exciting memory and ... always bring surprise to a wedding. On the updated fashion blog, ... veils for a big day . , Going out with friends ...
(Date:12/25/2014)... Dec. 24, 2014 (HealthDay News) -- Among early stage ... less than half of one percent will eventually develop ... analysis reveals. The finding comes from a review ... 1998 and 2007, and it suggests that the risk ... what experts had previously thought. "The frequency of ...
Breaking Medicine News(10 mins):Health News:BambooFlooringChina.com: click strand woven bamboo flooring promotion valid until Jan. 30, 2015. 2Health News:BellasDress.com’s Christmas Sale: Trendy Wedding Dresses With Big Discounts 2Health News:LunaDress Provides Professional Tips On Shopping Wedding And Prom Dresses 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 2Health News:Breast Cancer Chemo Tied to Small But Significant Leukemia Risk 3
... new resource - www.breastfeedinginsurance.com - where new and expectant mothers can access comprehensive information and tools to help them discover if ... ... , , ... ...
... March 11 As reported in today,s Wall ... with atrial fibrillation are now on notice that the over-zealous marketing ... not approved by the U.S. Food and Drug Administration (FDA) for ... and hospitals, decisions about treatment for their patients, heart conditions. ...
... Weakness in rotator cuff a warning sign, but exercise regimens ... -- As another baseball season nears, researchers report that preseason ... those pitchers at high risk of developing a shoulder injury ... cuff where, if they are weaker, players are more likely ...
... who had the flu while pregnant had smaller brains and ... patients with schizophrenia, a study at the University of Wisconsin-Madison ... Hill has found. The study, published online by the ... with monkeys that examines the effects of flu during pregnancy. ...
... , ... Medication and E-prescribing Company Depends on StrataScale’s Flagship Service for Reliable, Secure, Highly-scaleable ... ... fully automated managed hosting solution, today announced that Dr. Dispense, a point of ...
... ... ... VCAD is inviting the public to an evening presentation of fashion and costume history on ... 20th Century," covering the changing trends and styles of fashion from the 1890s through to ...
Cached Medicine News:Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 2Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 3Health News:Medela Announces Launch of New Insurance Reimbursement Resource for New and Expectant Mothers 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 2Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 3Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 4Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 5Health News:Whistleblower Alerts Americans to Dangers of Risky Unapproved Treatment for Atrial Fibrillation 6Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 2Health News:Pre-Season Test Spots Baseball Pitchers at Risk of Injury 3Health News:Mother's flu during pregnancy may increase baby's risk of schizophrenia 2Health News:Dr. Dispense Chooses World's First Fully Automated Managed Hosting Solution from StrataScale for All Outsourcing Needs 2Health News:Dr. Dispense Chooses World's First Fully Automated Managed Hosting Solution from StrataScale for All Outsourcing Needs 3Health News:Go Beyond Retro to Discover the World of 20th Century Fashion! 2
... has the right product for any patient ... intubated patients to patients with tracheotomies. These ... and critical care applications., ,The Unti-Mist ... patients and staff members. This entire product ...
... 1991 Intersurgical Incorporated manufactures ... heat and moisture exchangers, ... products, hand-held nebulizers and ... accessories and connectors for ...
... Since 1991 Intersurgical Incorporated ... filters, heat and moisture ... therapy products, hand-held nebulizers ... of accessories and connectors ...
... Ulti-Mist™ HME product line has the right ... to adults and from intubated patients to ... humidification for both anesthesia and critical care ... provide maximum protection for patients and staff ...
Medicine Products: